Study identifier:3591IL/0091
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label Study to Determine the Concentration of Meropenem in Plasma and Cantharidin-induced Skin Blister Fluid Following Repeated Intravenous Infusion of Meropenem 500 mg Every 8 Hours in Healthy Males
infectious diseases
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|